Buchan A, Skinner G R, Fuller A, Hartley C, Hallworth J, Stocker D, Melling J, Wiblin C
Vaccine. 1985 Mar;3(1):49-53. doi: 10.1016/0264-410x(85)90012-x.
The apparent increasing incidence of herpes simplex virus infections of the genital tract has focused attention on the efficacy of vaccination in preventing infection or modifying established disease. Results of an 'open trial' using a DNA-free inactivated virus subunit vaccine have shown that vaccination of subjects at risk of contracting infection from their sexual partner reduced the transmission rate from 34% in unvaccinated controls to 0.5%. In a separate study, vaccination of patients who had experienced their first overt attack of herpes genitalis (the initial clinical episode) had significantly fewer recurrences over the follow-up period of 12 months than the unvaccinated control group. The results, we feel, justify a placebo controlled trial.
生殖器单纯疱疹病毒感染的发病率明显上升,这使人们将注意力集中在疫苗接种在预防感染或改善已确诊疾病方面的功效上。一项使用无DNA灭活病毒亚单位疫苗的“开放试验”结果表明,对有从性伴侣感染风险的受试者进行疫苗接种,可将传播率从未接种疫苗的对照组的34%降至0.5%。在另一项研究中,对首次出现生殖器疱疹明显发作(初始临床发作)的患者进行疫苗接种,在12个月的随访期内,复发次数明显少于未接种疫苗的对照组。我们认为,这些结果证明有必要进行一项安慰剂对照试验。